Gadolinium-Based Contrast Agent-Related Toxicities.
Pasquini L, Napolitano A, Visconti E, Longo D, Romano A, Tomà P, Rossi Espagnet MC.
CNS Drugs. 2018 Mar;32(3):229-240. doi: 10.1007/s40263-018-0500-1.
Update on Gadolinium-Based Contrast Agent Safety, From the AJR Special Series on Contrast Media.
Starekova J, Pirasteh A, Reeder SB.
AJR Am J Roentgenol. 2024 Sep;223(3):e2330036. doi: 10.2214/AJR.23.30036. Epub 2023 Nov 15.
Gadolinium as an MRI contrast agent.
Kim HK, Lee GH, Chang Y.
Future Med Chem. 2018 Mar 1;10(6):639-661. doi: 10.4155/fmc-2017-0215. Epub 2018 Feb 7.
Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.
Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M.
AJNR Am J Neuroradiol. 2016 Jul;37(7):1192-8. doi: 10.3174/ajnr.A4615. Epub 2015 Dec 10.
Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms.
Rogosnitzky M, Branch S.
Biometals. 2016 Jun;29(3):365-76. doi: 10.1007/s10534-016-9931-7. Epub 2016 Apr 6.
Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.
Davies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P.
Arch Toxicol. 2022 Feb;96(2):403-429. doi: 10.1007/s00204-021-03189-8. Epub 2022 Jan 8.
Gadolinium Deposition Disease: Current State of Knowledge and Expert Opinion.
Semelka RC, Ramalho M.
Invest Radiol. 2023 Aug 1;58(8):523-529. doi: 10.1097/RLI.0000000000000977. Epub 2023 Apr 11.
Gadolinium Complexes as Contrast Agent for Cellular NMR Spectroscopy.
Sakol N, Egawa A, Fujiwara T.
Int J Mol Sci. 2020 Jun 5;21(11):4042. doi: 10.3390/ijms21114042.
Advances in gadolinium-based MRI contrast agent designs for monitoring biological processes in vivo.
Lux J, Sherry AD.
Curr Opin Chem Biol. 2018 Aug;45:121-130. doi: 10.1016/j.cbpa.2018.04.006. Epub 2018 May 9.
Gadolinium-based contrast agent-induced neurotoxicity: seeing is believing!
Chauhan G, Upadhyay A.
BMJ Case Rep. 2021 Jan 26;14(1):e241372. doi: 10.1136/bcr-2020-241372.
